Retatrutide is a 39-amino-acid synthetic peptide engineered as a tri-agonist of three structurally related class-B G-protein-coupled receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. It represents the third generation of incretin-receptor research peptides — following the single-agonist (Semaglutide) and dual-agonist (Tirzepatide) reference compounds — and exhibits a distinct downstream-signaling fingerprint in cellular models.

The 30mg / 3ml fill is configured for extended in-vitro protocols: triple-receptor binding-affinity matrices, comparative cAMP titration across the three receptor types, side-by-side characterization against the Semaglutide and Tirzepatide reference vials, and method-development work for HPLC and mass-spectrometry assays.

Each vial ships with a lot-matched Certificate of Analysis disclosing HPLC purity (>99%), ESI-MS mass confirmation, peptide content, and lot date. Store refrigerated at 2–8 °C.